Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour.
Grimpen
Florian
F
Medical Oncology Unit, Canberra Hospital, Garran, Australia.
Yip
Desmond
D
McArthur
Grant
G
Waring
Paul
P
Goldstein
David
D
Loughrey
Maurice
M
Beshay
Victoria
V
Chong
Guan
G
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D003951:Diagnostic Errors / Q000517:prevention & control; D016903:Drug Monitoring / Q000379:methods; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000556:secondary; D019298:Glucose-6-Phosphate / Q000031:analogs & derivatives; D006801:Humans; D000068877:Imatinib Mesylate; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology*; D049268:Positron-Emission Tomography; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011743:Pyrimidines / Q000494:pharmacology*; D017384:Sequence Deletion
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; C047515:2-fluoro-2-deoxyglucose-6-phosphate; D019298:Glucose-6-Phosphate; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit